– Study-entry data confirm deficiency in infant microbiomes compared to published literature – – The study, the largest of its kind, has enrolled 680 infants across the U.S., ahead of both schedule and budget due to an enthusiastic response from social media – – My Baby Biome is an observational study to determine gut biomarkers … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following investor conferences: Guggenheim’s 4th Annual Immunology and Neurology Day Date: Tuesday, November 15, 2022 … [Read more…]
Collaboration will integrate data into hospital patient workflows, supporting remote chronic care and population health management PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with HealthSnap, a leading full-service Virtual Care Management Platform for chronic disease management. The collaboration will enable more … [Read more…]
REMOTE-FIRST COMPANY/NASHVILLE–(BUSINESS WIRE)–NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative cloud-based healthcare technology solutions, today announced that management will participate in the Stephens Annual Investment Conference with a fireside chat scheduled to begin Tuesday, Nov. 15 at 3 p.m. Eastern Time. A recording of the event will be available at investor.nextgen.com and will … [Read more…]
FOXO LIFE signs insurance carrier to managing general agency agreement FOXO LIFE to begin distributing Haven Life insurance products through independent agent distribution channels MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced … [Read more…]
Company shared progress from its proprietary A-Kine™ platform for engineering of target-selective, cis-acting cytokine immunotherapies at 2022 PEGS Europe Protein and Antibody Engineering Summit Data demonstrate potent single-agent anti-tumor activity of immune cell-targeted interferons and interleukin-2 through remodeling of tumor microenvironments and cancer immunity cycle in syngeneic and humanized mouse models Orionis anticipates IND submission … [Read more…]
Delivers Simultaneous Multi-Region Neural Imaging of Free-Behaving Animals BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today announced the signing of the definitive agreement to purchase 100% of the shares of Neurescence Inc., an innovative provider of ultralight fiber-bundle Multiscopes™ for simultaneous multi-region, optical functional neuroimaging. Neurescence’s flagship product Chromatone™ moves illumination and detection hardware off … [Read more…]
Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology Company Has a Differentiated and Fast-growing, Commercial Drug Delivery Business; Significant Potential Upside from Immunotherapy Platform Post-transaction, Expects to be Fully Funded to Allow Key Data Read-Outs for Device and Immunotherapy Platform in Late 2024 Accelerates Access to Resources … [Read more…]
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 after the U.S. market closes on November 21, 2022. Enanta management will then … [Read more…]
Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and … [Read more…]
